Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BCL2 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BCL2 amplification (1)

BCL2 amplification (1)

›

BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
BCL2 overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
BCL2 overexpression	Acute Myelogenous Leukemia	BCL2 overexpression	Acute Myelogenous Leukemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BCL2 overexpression	Squamous Cell Carcinoma of Head and Neck	BCL2 overexpression	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3
BCL2 overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression	Diffuse Large B Cell Lymphoma	azacitidine oral Sensitive: C3 – Early Trials azacitidine oral Sensitive : C3	azacitidine oral Sensitive: C3 – Early Trials azacitidine oral Sensitive : C3
BCL2 overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BCL2 overexpression	Hodgkin Lymphoma	BCL2 overexpression	Hodgkin Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BCL2 overexpression	Non Small Cell Lung Cancer	BCL2 overexpression	Non Small Cell Lung Cancer	AZD2811 Resistant: D – Preclinical AZD2811 Resistant : D	AZD2811 Resistant: D – Preclinical AZD2811 Resistant : D
BCL2 overexpression	Hodgkin Lymphoma	BCL2 overexpression	Hodgkin Lymphoma	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D
BCL2 overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression	Diffuse Large B Cell Lymphoma	APG-2575 Sensitive: D – Preclinical APG-2575 Sensitive : D	APG-2575 Sensitive: D – Preclinical APG-2575 Sensitive : D
BCL2 overexpression	Acute Myelogenous Leukemia	BCL2 overexpression	Acute Myelogenous Leukemia	IACS-010759 Resistant: D – Preclinical IACS-010759 Resistant : D	IACS-010759 Resistant: D – Preclinical IACS-010759 Resistant : D
BCL2 overexpression	Multiple Myeloma	BCL2 overexpression	Multiple Myeloma	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D	bortezomib + A-1331852 Sensitive: D – Preclinical bortezomib + A-1331852 Sensitive : D
BCL2 overexpression	Acute Myelogenous Leukemia	BCL2 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D	osimertinib Sensitive: D – Preclinical osimertinib Sensitive : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	venetoclax + gefitinib Sensitive: D – Preclinical venetoclax + gefitinib Sensitive : D	venetoclax + gefitinib Sensitive: D – Preclinical venetoclax + gefitinib Sensitive : D
BCL2 overexpression	Lung Cancer	BCL2 overexpression	Lung Cancer	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D	gefitinib + ABT 263 Sensitive: D – Preclinical gefitinib + ABT 263 Sensitive : D